{"id":12778,"date":"2026-09-03T18:58:12","date_gmt":"2026-09-03T18:58:12","guid":{"rendered":"https:\/\/cryptonews.uk.com\/?p=12778"},"modified":"2026-09-03T18:58:12","modified_gmt":"2026-09-03T18:58:12","slug":"hyperliquid-strategies-expands-equity-facility-to-2-5b","status":"publish","type":"post","link":"https:\/\/cryptonews.uk.com\/?p=12778","title":{"rendered":"Hyperliquid Strategies expands equity facility to $2.5B"},"content":{"rendered":"

<\/p>\n

\n

Hyperliquid Strategies, a Nasdaq-listed company using equity sales to build a treasury of Hyperliquid’s HYPE token, has expanded its committed-equity facility with Chardan Capital Markets to $2.5 billion from $1 billion.<\/p>\n

\n

Related Reading<\/span><\/p>\n

A $1 billion HYPE treasury bet to hit public markets before knowing how liquidity will hold up<\/h3>\n<\/p>\n

<\/span> <\/div>\n

The immediate runway before a new dilution constraint applies is far smaller than the headline commitment. Hyperliquid Strategies’ annual report disclosed $646.6 million of gross facility proceeds through June 30, followed by another $117.1 million raised through facility shares after quarter-end. Together, those figures show at least $763.7 million of proceeds, leaving no more than about $236.3 million before aggregate sales reach $1 billion. Any later sales would reduce that headroom, and the September 1 filing did not provide an updated utilization total.<\/p>\n

Once aggregate facility sales pass $1 billion, the issue price becomes decisive. Under the operative amendment, Hyperliquid Strategies cannot complete a sale if doing so would take the aggregate number of facility shares issued at prices below $12.02 above 42,641,847. That exchange cap equals 19.99% of the company’s pre-amendment voting power or outstanding common shares. Issuance above the cap requires stockholder approval unless that approval is not required under Nasdaq rules.<\/p>\n

\"Infographic\"Infographic<\/p>\n

The restriction does not, however, translate into a clean dollar ceiling. Shares sold at $12.02 or more do not fall under the price-specific cap, while the remaining capacity for lower-priced sales depends on how many qualifying shares already count toward it. The filings disclose aggregate shares, proceeds and an average price, but not the transaction-level price mix needed to calculate that count. The amendment also permits the cap to be reduced by other transactions that Nasdaq treats as part of the same issuance.<\/p>\n